Kinloch Capital LLC Makes New $4.26 Million Investment in Kenvue Inc. $KVUE

Kinloch Capital LLC bought a new stake in Kenvue Inc. (NYSE:KVUE) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 223,159 shares of the company’s stock, valued at approximately $4,265,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Johnson Financial Group Inc. purchased a new stake in Kenvue during the 2nd quarter worth approximately $26,000. CoreCap Advisors LLC increased its position in shares of Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after acquiring an additional 591 shares during the period. Elyxium Wealth LLC acquired a new stake in shares of Kenvue in the fourth quarter valued at $26,000. Physician Wealth Advisors Inc. raised its stake in shares of Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after acquiring an additional 618 shares in the last quarter. Finally, MV Capital Management Inc. purchased a new position in Kenvue in the fourth quarter valued at $28,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Performance

NYSE KVUE opened at $19.41 on Tuesday. The business’s 50-day moving average price is $19.08 and its 200 day moving average price is $18.21. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $21.63. The firm has a market cap of $37.27 billion, a P/E ratio of 22.30, a P/E/G ratio of 1.36 and a beta of 0.47. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The company had revenue of $3.96 billion for the quarter, compared to analysts’ expectations of $3.97 billion. During the same quarter last year, the company earned $0.29 EPS. Kenvue’s revenue for the quarter was up 3.0% compared to the same quarter last year. On average, equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th will be paid a $0.21 dividend. This is a boost from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date is Wednesday, August 12th. This represents a $0.84 annualized dividend and a dividend yield of 4.3%. Kenvue’s dividend payout ratio (DPR) is 96.55%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on KVUE shares. Wall Street Zen lowered Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. UBS Group cut their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, Barclays upped their price target on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $19.27.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.